ライフサイエンスコーパス: propranolol

1 rred after local beta-adrenoceptor blockade (propranolol).

2 ta-AR antagonists (1 muM prazosin and 10 muM propranolol).

3 renoreceptor blockade (5 mM yohimbine + 1 mM propranolol).

4 (ISO), or the beta-adrenoceptor antagonist, propranolol.

5 d DR, and DH Fos was decreased by systemic S-propranolol.

6 ation was not blocked with betaAR antagonist propranolol.

7 Both are prevented by treatment with propranolol.

8 72 months) underwent treatment with systemic propranolol.

9 o better than aspirin, dihydroergotamine, or propranolol.

10 peridin-1-yl)propan-2-ol (A-core)] recalling propranolol.

11 olff-Parkinson-White, comparing digoxin with propranolol.

12 r injection; P<0.0001) and were inhibited by propranolol.

13 rence in infants treated with digoxin versus propranolol.

14 c prophylaxis of SVT in infants: digoxin and propranolol.

15 ts metabolic stability was much greater than propranolol.

16 er(24) unless the mice were pre-treated with propranolol.

17 he study, 27 randomized to digoxin and 34 to propranolol.

18 tation since these effects were abolished by propranolol.

19 TSD, but not necessarily in combination with propranolol.

20 o have poorer outcomes than those not taking propranolol.

21 All effects on the CR were wholly blocked by propranolol.

22 s effect when administered concurrently with propranolol.

23 at beta(2)AR was competitively inhibited by propranolol.

24 These effects were blocked by propranolol.

25 of high-dose (80 mg) versus low-dose (20 mg) propranolol.

26 by previous administration of yohimbine and propranolol.

27 the addition of the beta-adrenergic blocker propranolol.

28 nstable wild-type receptor by the antagonist propranolol.

29 onstants between immobilized AGP and R- or S-propranolol.

30 the addition of the beta-adrenergic blocker propranolol.

31 propranolol-d7 and varied concentrations of propranolol.

32 1 wk of oral treatment with the beta-blocker propranolol.

33 the full SERS spectral data and the level of propranolol.

34 space could be correlated with the level of propranolol.

35 ther resection of the carotid sinus nerve or propranolol.

36 and in vitro ADME-tox profiles comparable to propranolol.

37 n the placebo group and the groups receiving propranolol.

38 ) included patients initiating bisoprolol or propranolol.

39 sated cirrhosis before and after intravenous propranolol (0.15 mg/kg): 194 patients had an HVPG >/=10

40 injection of vehicle, mifepristone 30 mg/kg, propranolol 10 mg/kg, or both.

41 were mitigated by systemic administration of propranolol (10 mg/kg, i.p.), a beta-noradrenergic recep

42 I, Naples, Italy, were treated with systemic propranolol (2 mg/kg body weight per day).

43 1), the beta-adrenergic receptor antagonist propranolol (2 mug) or vehicle (Experiment 2), or the be

44 The second patient was taking amiodarone and propranolol; 2 hrs after receiving sofosbuvir and daclat

45 h POTS (n=54) underwent acute drug trials of propranolol 20 mg orally and placebo, on separate mornin

46 To evaluate the efficacy of propranolol (3 mg/kg/day) in the treatment of periocular

47 A single oral dose of propranolol (40 mg) significantly increased beta band (1

48 o or the noradrenergic beta-receptor blocker propranolol (40 mg).

49 Osmotic mini pumps containing either propranolol (5 mg/kg/d) or vehicle alone were implanted

50 nergic and 5-HT1A/1B receptor antagonist), R-propranolol (5-HT1A/1B receptor antagonist), or racemic

51 ymptoms at 2 hours was greater with low-dose propranolol (-6 versus -2 arbitrary units; P=0.041).

52 ue sections of mice intravenously dosed with propranolol (7.5 mg/kg).

53 d antagonist), alone and in combination with propranolol (a beta-adrenergic blocker), both given syst

54 microglia and macrophages were prevented by propranolol, a beta-adrenergic receptor antagonist.

55 Propranolol, a generic beta-adrenergic antagonist, decre

56 Propranolol, a non-selective beta-blocker, has been foun

57 ive alpha-adrenergic receptor antagonist, or propranolol, a nonselective beta-adrenergic receptor ant

58 Propranolol, a nonselective beta-adrenergic receptor blo

59 thin tissue sections from animals dosed with propranolol, adhered to an adhesive tape substrate, prov

60 The beta-adrenergic receptor antagonist propranolol, administered in conjunction with memory rea

61 RANKL expression by MSCs decreased after propranolol administration and increased after isoproter

62 Moreover, propranolol administration dampened the stress-induced i

63 Whether propranolol administration for 1 year after injury provi

64 n contrast, neither intra-BLA nor intra-mPFC propranolol affected delayed extinction learning.

65 -118 551 (beta1 and beta2 antagonists), or S-propranolol alone.

66 ne, terbutaline, metaproterenol, salmeterol, propranolol, alprenolol, bisoprolol, ICI 118,551, and bu

67 Propranolol also suppressed PARP1 activation in peripher

68 Both propranolol and captopril significantly decreased the du

69 In the phase 2 study, both propranolol and captopril significantly increased the th

70 nergic-induced arrhythmias by beta-blockers (propranolol and carvedilol), flecainide, and the neurona

71 Here we show that propranolol and carvedilol, two beta-blocker drugs that

72 f interaction were occurring between R- or S-propranolol and HDL at 37 degrees C: saturable binding w

73 e the true binding strength between R- and S-propranolol and HPLC columns containing immobilized AGP.

74 0), or medical reduction of portal pressure (propranolol and isosorbide-5-mononitrate; n = 95).

75 face sampling exemplified by the analysis of propranolol and its hydroxypropranolol glucuronide phase

76 e, provided semiquantitative information for propranolol and its hydroxyproranolol glucuronide metabo

77 tem were established using the drug molecule propranolol and its isotope labeled internal standard in

78 al detection to determine relative levels of propranolol and metabolites present.

79 Propranolol and metoprolol (highly permeable compounds)

80 In sympathetic neuronal cell cultures, both propranolol and metoprolol increased axon outgrowth but

81 Propranolol and metoprolol showed a rapid absorption and

82 Propranolol and nadolol are equally effective, whereas s

83 However, after treatment with propranolol and PKA, the R21C cTnI mutation reduced (R21

84 ality or psychophysiological measures in the propranolol and placebo groups.

85 Instead, we suggest that propranolol and salbutamol may affect both tremor and co

86 The nonselective beta-blocker propranolol and the beta(1)-antagonist metoprolol both i

87 s, the sympathetic nervous system (SNS) with propranolol and the hypothalamic-pituitary-adrenal axis

88 Comparison of the DESI-MS/MS signal for propranolol and the radioactivity attributed to proprano

89 g nonselective beta-blockers, including oral propranolol and topical timolol.

90 high-density lipoprotein (HDL) to the drugs propranolol and verapamil.

91 g contaminants (caffeine, ciprofloxacin, and propranolol) and two model compounds (fluorescein and su

92 idine), beta-adrenergic receptor antagonist (propranolol), and beta(1)- and beta(2)-antagonist (betax

93 d by previous administration of prazosin and propranolol, and 4) epinephrine in which both alpha2- an

94 ency (HF) fraction of HRV in the presence of propranolol, and a decrease in expression of the G-prote

95 e beta1- and beta2-adrenergic receptors with propranolol, and by blocking protein kinase A with KT572

96 in vivo can be blocked with the beta-blocker propranolol, and by knockdown of RANK expression in MDA-

97 acetaminophen, ciprofloxacin, trimethoprim, propranolol, and carbamazepine (>80%) was achieved withi

98 Transformation of trimethoprim, propranolol, and carbamazepine was attributed to direct

99 rst cardiac events for atenolol, metoprolol, propranolol, and nadolol were 0.71 (0.50 to 1.01), 0.70

100 hotolysis rates for atenolol, carbamazepine, propranolol, and sulfamethoxazole in wetland water under

101 ums and by Ca(2+), Zn(2+), N-ethylmaleimide, propranolol, and the sphingoid bases sphingosine and sph

102 milar to the effect of the betaAR antagonist propranolol, and this effect was reversed by the mGlu3-n

103 a limit of detection of 2.36 ng/mL (7.97 nM) propranolol, and this is significantly lower (>25 times)

104 etermined limits of detection for serotonin, propranolol, and tryptophan were 51, 37, and 280 nM, res

105 included clonidine, flunarizine, pizotifen, propranolol, and valproate.

106 550 g were administered either beta-blocker, propranolol, angiotensin converting enzyme inhibitor, ca

107 Propranolol appears to be tremendously efficacious with

108 Both riluzole and propranolol are efficient sodium channel blockers.

109 The current treatments, corticosteroid or propranolol, are administered for several months and can

110 rational redesign of a given pharmaceutical (Propranolol as an example).

111 S, we chose the beta-adrenergic blocker drug propranolol as the target analyte.

112 Propranolol at 3 mg/kg/day was clinically and radiologic

113 corresponding to the decrease in transfer of propranolol at an aqueous-1,2-dichloroethane interface.

114 e combined administration of oxandrolone and propranolol at the same doses, for 1 year after burn.

115 TAC mice treated with propranolol attenuated the rate of (18)F-FDG uptake, dim

116 Combined administration of oxandrolone and propranolol attenuates burn-induced growth arrest in ped

117 e of four propranolol regimens (1 or 3 mg of propranolol base per kilogram of body weight per day for

118 traditional beta-blockers (eg, atenolol and propranolol), because there are currently no mortality a

119 n of the beta-adrenergic receptor antagonist propranolol before memory retrieval, but not after (duri

120 seeking behavior on ED1 following 10 mg/kg S-propranolol (beta-adrenergic and 5-HT1A/1B receptor anta

121 Propranolol (beta-adrenergic receptor (beta-Ad) antagoni

122 were treated in counter-balanced order with propranolol (beta-AR antagonist), terazosin (alpha1-AR a

123 ules (R)-Naftopidil (alpha1-blocker) and (S)-Propranolol (beta-blocker) as a key step via AKR of sing

124 these dilatations were inhibited by 10(-7) m propranolol (betaAR antagonist) which otherwise had no e

125 The beta-receptor antagonist propranolol blocked the inhibitory effect of (R)-albuter

126 drenoceptor activity with local infusions of propranolol blocked the memory retrieval impairment indu

127 ioma shrinkage is rapidly observed with oral propranolol, but a minimum of 6 months of therapy is rec

128 HMG-CoA reductase inhibitors, combined with propranolol, can cause mitochondrial toxicity, yielding

129 tting, we demonstrated that isoproterenol, S-propranolol, CGP-12177 [4-[3-[(1,1-dimethylethyl)amino]2

130 in asthma, showing no significant effect of propranolol compared with placebo on either methacholine

131 ) heart rates were significantly lower after propranolol compared with placebo.

132 Average propranolol concentrations determined with the laser "cu

133 s containing the same fixed concentration of propranolol-d7 and varied concentrations of propranolol.

134 nt, which contained a known concentration of propranolol-d7 as an internal standard.

135 of the beta1-, beta2-adrenoceptor antagonist propranolol decreases cardiac work and resting energy ex

136 +/- 30 ml min(-1)) or combined phentolamine/propranolol (Delta213 +/- 25 ml min(-1); P < 0.05 for bo

137 bited a 6.5-times higher current density for propranolol detection due to the enhanced ion flux arisi

138 Higher-dose propranolol did not further improve, and may worsen, sym

139 At 2 d after propranolol discontinuation, beta-receptor sensitivity a

140 men is safe up to a size of 5.5 cm and that propranolol does not inhibit aneurysm expansion.

141 Propranolol during reactivation specifically reduced the

142 structures were active (but not modulated by propranolol) during memory reactivation.

143 /kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggesting a need for new

144 /kg/h), or a combination of phentolamine and propranolol (each 1 mg/kg/h), suggesting a need for new

145 The bound concentration of propranolol enantiomers in the presence of AGP was found

146 ransfer potential of the uncomplexed form of propranolol enantiomers.

147 Propranolol enhanced cocaine reinforcement and reduced p

148 Collectively, these data suggest that propranolol exerts its suppressive effects on hemangioma

149 Four months of treatment with oral propranolol for eyelid infantile capillary hemangiomas l

150 d to be greater for (S)-propranolol than (R)-propranolol for solutions containing constant concentrat

151 were treated with varying concentrations of propranolol for up to 4 days.

152 pranolol and the radioactivity attributed to propranolol from WBA sections indicated nominal agreemen

153 Propranolol given for 1 month postburn blunts this respo

154 owever, in the placebo group, but not in the propranolol group, memory vividness significantly decrea

155 Propranolol has a significantly better QTc shortening ef

156 e combined administration of oxandrolone and propranolol has added benefit.

157 The nonselective beta-blocker propranolol has become first-line therapy for the treatm

158 Propranolol has been found to be effective in treatment

159 Oral propranolol has been used to treat complicated infantile

160 Thus, propranolol has diverse effects on KSHV-infected cells,

161 Sugar starter cores were layered with propranolol HCl and subsequently coated with Kollicoat S

162 Propranolol HCl, as well as very small sugar particles f

163 that blocking beta-adrenergic signaling with propranolol hydrochloride disrupts angiosarcoma cell sur

164 l hydrochloride, the binding of (S)- and (R)-propranolol hydrochloride to the protein results in a de

165 A combination of propranolol hydrochloride, 40 mg 3 times a day, paclitax

166 The patient was immediately administered propranolol hydrochloride, 40 mg twice a day, as his wor

167 ted with daily intraperitoneal injections of propranolol hydrochloride.

168 Known adverse events associated with propranolol (hypoglycemia, hypotension, bradycardia, and

169 Propranolol images of the tissue sections using DESI-MS/

170 before and after systemic beta-blockade with propranolol in 17 young men, 17 young women and 15 postm

171 ly relevant concentrations of metoprolol and propranolol in blood samples were measured over several

172 (5-HT1A/1B receptor antagonist), or racemic propranolol in both male and female rats.

173 stem for online and absolute quantitation of propranolol in mouse brain, kidney, and liver thin tissu

174 omized placebo-controlled crossover trial of propranolol in patients with mild-to-moderate asthma rec

175 between the two techniques for the amount of propranolol in the brain, lung, and liver.

176 s in transduction during beta-blockade using propranolol in YW, YM and PMW.

177 in wild-type mice after co-administration of propranolol, indomethacin, and L-NAME.

178 Additionally, propranolol induced lytic gene expression in association

179 o the nucleus tractus solitarii (NTS) and by propranolol infused into the basolateral complex of the

180 We used bilateral intracranial infusions of propranolol into either the infralimbic division of the

181 Oral propranolol is now the first-line treatment, which shoul

182 high risk for subsequent cardiac events, and propranolol is the least effective drug in this high-ris

183 Treatment with propranolol led to a dose dependent cytotoxic effect in

184 Propranolol may be a helpful adjunct to behavioral thera

185 Propranolol may be a useful adjunct to behavioral therap

186 Recent evidence has suggested that propranolol may be effective in patients suffering from

187 tect and image the distribution of the known propranolol metabolites were unsuccessful.

188 with small molecular changes as compared to propranolol molecule were generated by a nontargeted pho

189 of the tumor before and after only 1 week of propranolol monotherapy revealed a reduction in the prol

190 eters of 382 LQT1/LQT2 patients initiated on propranolol (n = 134), metoprolol (n = 147), and nadolol

191 e of 40 mg of the noradrenergic beta-blocker propranolol (n = 15), double-blind and placebo-controlle

192 randomized to control (n = 89) or 4 mg/kg/d propranolol (n = 90) for 12 months postburn.

193 ic patients receiving metoprolol compared to propranolol/nadolol.

194 ng the effects of the beta-adrenergic agents propranolol (non-selective beta-antagonist) and salbutam

195 The effect of the noradrenergic inhibitor propranolol on (14)C-FBnTP response to cold stimulation

196 The opposite direction of the effects of propranolol on corticomuscular coherence and tremor, and

197 s provide a plausible mechanism of action of propranolol on regression of infantile hemangiomas.

198 etreatment with 1 mg (100 g body weight)(-1) propranolol or 6 mg (100 g body weight)(-1) iopanoic aci

199 ered the beta-adrenergic receptor antagonist propranolol or a placebo before they reactivated previou

200 by either beta-adrenoreceptor blockade with propranolol or adrenalectomy.

201 beta-Adrenoceptor blockade with propranolol or inhibition of its downstream cAMP/PKA sig

202 e then intraperitoneally injected by saline, propranolol or isoproterenol.

203 ective actually are beta3-sparing, including propranolol or nadolol.

204 The beta-receptor blocker propranolol or PKA inhibitor Rp-cAMPS blocks the effects

205 s underwent a 6- to 8-week dose titration of propranolol or placebo as tolerated to a maximum of 80 m

206 macological blockade of either sympathetic - propranolol - or parasympathetic - methylatropine - sign

207 beta-adrenergic antagonists phentolamine and propranolol, or 3) adrenergic blockade plus cholinergic

208 common beta-blockers (atenolol, metoprolol, propranolol, or nadolol).

209 infants with periocular IH were treated with propranolol (oral) for 2-12 months (mean: 7.1 months).

210 ve HPAC columns with reproducible binding to propranolol over 4-5days of continuous operation at pH 7

211 f patients on digoxin and 31% of patients on propranolol (P=0.25).

212 patients on digoxin and 67% for patients on propranolol (P=0.34), and there were no first recurrence

213 s of trial treatment, the regimen of 3 mg of propranolol per kilogram per day for 6 months was select

214 nucleotides (ATP and CTP), N-ethylmaleimide, propranolol, phenylglyoxal, and divalent cations (Ca(2+)

215 Concurrent administration of propranolol prevents this effect.

216 rescued the IED; animals receiving intra-BLA propranolol prior to immediate extinction showed less sp

217 s after intravenous administration of either propranolol (PROP), or glycopyrrolate (GLYC), or PROP an

218 clotrimazole (CTZ), clofibric acid (CFA) and propranolol (PRP), found responses to IBU and CFA, but n

219 ng was subsequently used to provide accurate propranolol quantification within all biofluids with hig

220 fluids spiked with varying concentrations of propranolol ranging from 0 to 120 muM, and clear trends

221 of 88% of patients who received the selected propranolol regimen showed improvement by week 5, versus

222 y assigned to receive placebo or one of four propranolol regimens (1 or 3 mg of propranolol base per

223 nterestingly, intra-BLA, but not intra-mPFC, propranolol rescued the IED; animals receiving intra-BLA

224 hat systemic beta-adrenoceptor blockade with propranolol rescues the IED, but impairs delayed extinct

225 9.9-fold for 1 microM CGP 12177 and 1 microM propranolol, respectively) and abolished in beta1-adreno

226 presence of 1 microM CGP 12177 and 1 microM propranolol, respectively.

227 intra-arterial infusions of phentolamine and propranolol, respectively.

228 f 2.7 and 1.3 x 10(5) M(-1) for (S)- and (R)-propranolol, respectively.

229 In rats with coronary artery ligation, propranolol reversed heart failure-induced ventricular m

230 of stressed animals with the beta-antagonist propranolol reversed the stress-induced macrophage infil

231 the beta-noradrenergic receptor antagonist, propranolol, reversed the decrease, suggesting that the

232 Combined use of oxandrolone and propranolol shortened the period of growth arrest by 84

233 removed from water, while the organic cation propranolol showed biouptake similar to that of TCC.

234 Low-dose oral propranolol significantly attenuated tachycardia and imp

235 Data indicate that 21 days of propranolol significantly decreased the b-wave amplitude

236 Propranolol significantly diminished the effect of cold

237 In contrast, the antagonist propranolol significantly increased maternal aggression

238 revealed that noradrenergic blockade (40 mg propranolol) significantly increased metacognitive perfo

239 The drugs are propranolol, simvastatin, norfloxacin, and warfarin, whi

240 cacy and safety of a pediatric-specific oral propranolol solution in infants 1 to 5 months of age wit

241 ction and quantification of the beta-blocker propranolol spiked into human serum, plasma, and urine a

242 In this hypermetabolic, hypoglycaemic state, propranolol stimulated a rise in P aC O2, suggestive of

243 gy state were inhibited by coincubation with propranolol, suggesting involvement of beta-adrenergic s

244 beta-antagonist (propranolol) suppressed subchondral bone loss and osteoc

245 sence of AGP was found to be greater for (S)-propranolol than (R)-propranolol for solutions containin

246 nt from baseline to 2 hours was greater with propranolol than placebo (median, -4.5 versus 0 arbitrar

247 After propranolol, the HVPG decreased significantly in both gr

248 tenuated by the beta-adrenoceptor antagonist propranolol, the mixed alpha-/beta-adrenoceptor antagoni

249 Propranolol therapy for infantile hemangiomas (IH) is no

250 Propranolol therapy is effective in life-threatening IH

251 These data bring into question whether propranolol through inhibition of beta-adrenergic recept

252 Simultaneous administration of atropine and propranolol to block parasympathetic and sympathetic bra

253 Control animals treated with intravenous propranolol to block sympathetically mediated chronotrop

254 r 60-90 s) in rats treated with atropine and propranolol to eliminate changes in heart rate.

255 a(V)1.1 channels in vivo, and treatment with propranolol to inhibit beta-adrenergic receptors reduced

256 disturbances resulting from systemic use of propranolol to treat infantile hemangioma.

257 Propranolol-treated mice demonstrated a 50% reduction in

258 ing RNA isolated from retinas of control and propranolol-treated pups.

259 After propranolol treatment (-PKA), the pCa-tension relationsh

260 Propranolol treatment also did not change retinal expres

261 Propranolol treatment decreased serum FGF23 and loss of

262 Propranolol treatment for 12 months after thermal injury

263 e of incomplete development, the efficacy of propranolol treatment in retinopathy needs to be evaluat

264 cal trials are currently ongoing to evaluate propranolol treatment in stage 2 ROP patients who tend t

265 We used propranolol treatment of mice to reduce the level of tro

266 less future recovery of responding, whereas propranolol treatment reduced the benefit seen with comp

267 d norepinephrine levels in the pancreas, and propranolol treatment reversed glucose intolerance in th

268 Long-term propranolol treatment significantly reduced the percenta

269 Propranolol treatment via three routes and up to 30 time

270 Three routes of propranolol treatment were assessed from P12 to P16: ora

271 e of the treatment approaches at any dose of propranolol (up to 60 mg/kg/day) were effective in preve

272 Experiments with propranolol used a double-blind, placebo-controlled cros

273 re very few adverse effects from the dose of propranolol used.

274 ine or histamine challenge after exposure to propranolol versus placebo.

275 tamine challenge was partially attenuated by propranolol versus placebo: FEV1% mean difference, 5.28

276 ea under the naphthalene ring vibration from propranolol was 133.1 ng/mL (0.45 muM), 156.8 ng/mL (0.5

277 Propranolol was compared with valproate as well as behav

278 This trial showed that propranolol was effective at a dose of 3 mg per kilogram

279 ric detection of the protonated beta-blocker propranolol was explored at arrays of nanoscale interfac

280 In contrast, S-propranolol was most effective in females in reducing dr

281 The QTc shortening with propranolol was significantly greater than with other be

282 Propranolol was stopped in 1 case for hypotension and in

283 al of 10% of patients in whom treatment with propranolol was successful required systemic retreatment

284 aximum length of treatment was 4 months, and propranolol was suspended when complete regression of le

285 ent events differed by drug (p = 0.004), and propranolol was the least effective compared with the ot

286 mination of the enantiomers of a basic drug, propranolol, was achieved at a micro liquid-liquid inter

287 and trimethoprim, while sulfamethoxazole and propranolol were attenuated mainly via photolysis.

288 Patients with refractory ascites taking propranolol were found to have poorer outcomes than thos

289 udy, patients with refractory ascites taking propranolol were found to have poorer outcomes, perhaps

290 sing scan rate, useful whole-body images for propranolol were obtained from the tissues even at 7 mm/

291 During summer, atenolol, metoprolol, and propranolol were rapidly attenuated in the pilot-scale s

292 Amiodarone and propranolol were stopped, but the patient continued rece

293 Two benzazaborinine analogues of propranolol were synthesized and extensively profiled in

294 formation rates increased for metoprolol and propranolol when algal photosynthesis was supported by i

295 l tumors may confer similar efficacy as oral propranolol while reducing systemic effects.

296 n through co-treatment with the beta-blocker propranolol, while leaving the peripheral effect intact,

297 We tested the hypothesis that propranolol will attenuate the tachycardia and improve s

298 nts (n = 15) received a single dose of 40 mg propranolol without memory reactivation.

299 Memory reactivation alone or propranolol without reactivation had no effect on subseq

300 Propranolol worsened AILI.